Summary The aim of the study was to determine the maximum tolerated dose (MTD) 
Patients with non-small-cell lung cancer (NSCLC) are often diagnosed with locally advanced or disseminated disease despite few or no symptoms. Median survival for patients with advanced locoregional inoperable NSCLC is 8-10 months (Bunn, 1991) , for patients with metastatic NSCLC median survival is 6 months (Ihde, 1992) . To improve the prognosis of patients with inoperable NSCLC, chemotherapy with or without radiotherapy is the only currently available treatment modality. A meta-analysis of results of (combination) chemotherapy trials in these patients has shown improvement of survival compared with best supportive care only (Souquet et al., 1993) , although the benefit at 1 year is only marginal (Grilli et al., 1993) . A limited number of cytotoxic drugs induce more than 15% objective responses as single agent in NSCLC. One of these agents is epirubicin, the 4' epimer of the anthracycline antibiotic doxorubicin (DXR). The major acute dose-limiting toxicity (DLT) of anthracyclines is myelosuppression; the most important chronic DLT is cardiotoxicity which is manifested as irreversible cardiomyopathy (Plosker et al., 1993) . In previous comparative studies vs DXR, epirubicin has demonstrated less bone marrow and cardiac toxicity at equipotent dosages; its major acute DLT is myelosuppression (Launchbury and Habboubi, 1993) . In NSCLC high-dose epirubicin (> 120 mg m-2) as a single agent has shown promising objective response rates of 21-56% (Wils et al., 1990; Martoni et al., 1991; Villar et al., 1991; Feld et al., 1992; Smit et al., 1992) . One way to improve these results is to combine high-dose epirubicin with other active agents in NSCLC. Vinorelbine (nor-5'anhydrovinblastine) is a new semisynthetic vinca alkaloid chemically different from vinblastine by a substitution of the catharanthine moiety. Like other vinca alkaloids, vinorelbine inhibits tubulin polymerisation into microtubules, and as in the parent vinblastine, neurotoxicity appears to be mild (Krikorian et al., 1991; Zhou et al., 1992) . Vinorelbine has been under investigation in phase II trials and showed activity against NSCLC with response rates ranging from 14% to 65% (Cvitovic et al., 1992; Sorensen, 1992; Lilenbaum et al., 1993) . The Table V . Twenty-eight cycles were associated with nausea/vomiting grade I-III despite prophylactic anti-emetic treatment. The median duration of nausea/vomiting was 2.5 days with a range of 1-8 days. From their second or third cycle on, 16 out of 21 patients showed grade I or II phlebitis. Only two of these patients had to be treated with analgesics. Neurotoxicity was not observed. Cardiac toxicity could not be excluded in one patient who complained of fatigue and slight shortness of breath. LVEF measured by MUGA scan decreased from 74% to 50% after four courses corresponding to a total dose of 416 mg m-2 epirubicin. This patient eventually died of progressive disease measured on chest radio- graph, however, without clinical signs of congestive heart failure. Sixteen patients had to be hospitalised during their treatment for a total of 24 admissions. Reasons for hospital admission were red blood cell transfusion (12 patients), neutropenic fever (four patients), pneumonia (one patient) and ischaemic colitis (one patient). Although tumour response was not an end point of this study, we observed two partial responses (one in level II and one in level III), and ten patients with stable disease out of 20 evaluable patients. Response durations were 12 and 4 weeks. Survival of this group showed a range of 3-106 weeks with a median of 21 weeks (with one patient still alive at time of evaluation).
Discussion
The objective of this study was to determine the MTD of the combination of high-dose epirubicin and vinorelbine in chemotherapy-naive patients with grade IIIB-IV NSCLC. We found neutropenia, neutropenic fever and thrombocytopenia on day 8 as dose-limiting toxicities. In this phase I study we determined the MTD at 135 mg m2 epirubicin (day 1) combined with 25 mg m-2 vinorelbine (days 1 and 8). Leucocyte, neutrophil and platelet nadirs occurred on day 12 with dose-related myelosuppression. In only one out of 84 cycles haematological recovery was not complete before day 22. Non-haematological toxicity consisted mainly of nausea and vomiting (in spite of prophylactic anti-emetic treatment), although neither this nor a frequently observed phlebitis of the infusion vein has been a major problem. Cardiac toxicity was possibly encountered in only one out of 21 patients; the decrease in LVEF was not accompanied by clinical signs. Analysis of other high-dose epirubicin studies has shown that high incidences of decreasing LVEF go together with low incidences of congestive heart failure (Feld et al., 1992) . Nielsen et al. (1990) conclude from their study of 135 epirubicin-treated patients that LVEF is of no predictive value for congestive heart failure, and should only be measured if there is clinical suspicion of cardiac disease. For higher cumulative dosages endomyocardial biopsy may be more indicative for congestive heart failure than LVEF (Torti et al., 1986) . A considerable risk of cardiac toxicity was found in patients treated with a cumulative dose of epirubicin above 1000 mg m2 (Shepherd et al., 1989) . Therefore, it is questionable whether MUGA scans should be performed routinely in patients who are treated at lower cumulative dosages. In the present study no neurotoxicity and no treatment-related deaths were observed. The MTD for epirubicin and vinorelbine as established in this phase I study differs from an earlier report (Gridelli et al., 1993) . They found an MTD of 60 mg m-2 epirubicin without granulocyte colony-stimulating factor (G-CSF) and an MTD of 90 mg m-2 epirubicin with G-CSF with a fixed dose of 25 mg m-2 vinorelbine. Myelosuppression was the dose-limiting toxicity for both treatment groups, as it was in our study. Gridelli et al. (1993) defined MTD as the dose that caused myelotoxicity grade III in 50% of cases and grade IV in 20% of cases. In our definition of MTD the duration of the neutropenia was more important than the degree of nadir, which might explain the difference in MTD between these two studies. Myelotoxicity in our study was comparable with that reported for single-agent epirubicin at dosages of 160-180 mg m-2 (Feld et al., 1992) . From data of this phase I study, we conclude that combination treatment of high-dose epirubicin with vinorelbine causes considerable toxicity. In dose level III only two out of six patients could receive a full-dose second course compared with four out of six patients at dose level II. Also, the RDI in these two levels were almost identical owing to more dose reductions in the higher dose level. Both arguments suggest that dose level II (epirubicin 120 mg m-2 combined with vinorelbine 20 mg m-2) is the recommended dose for phase II studies. However, as leuco-and neutropenia are the major toxicities of this regimen, a more obvious combination might be high-dose epirubicin with gemcitabine or carboplatin since these drugs cause less leuco-and neutropenia compared with vinorelbine.
